Programmable mRNA therapeutics for cancer and autoimmune disease using genetic circuits
Biotech📍 Boston, MAFounded 2017
Current Valuation
$550M
as of 2025-Q3
PRIVATE
IPO Outlookprivate
Is Strand Therapeutics going public?
No. Strand Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Strand Therapeutics' valuation in 2026?
Strand Therapeutics is valued at $550M as of 2025-Q3, set by its Series B ($153M, Aug 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Strand Therapeutics filed an S-1?
No public S-1 is on file for Strand Therapeutics.
Who are Strand Therapeutics' investors?
Strand Therapeutics' investors include Kinnevik, ICONIQ Capital, FPV Ventures, Playground Global, ANRI, Redmile Group and 5 more.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Strand Therapeutics is an MIT-spinout developing programmable mRNA therapeutics built on genetic circuits that can sense cellular state and conditionally activate therapeutic payloads. Lead asset STX-001 is in Phase 1 clinical trials for solid tumors via intratumoral delivery, with multiple RECIST responses reported in June 2025. Founded in 2017 by MIT synthetic biologists Jacob Becraft (CEO) and Tasuku Kitada (President & Head of R&D), with Ron Weiss (Becraft's PhD advisor) as cofounder and current advisor. Raised a $153M Series B in August 2025 led by Kinnevik at an estimated $550M post-money valuation (Forbes), up from $359M in November 2024 and just $15.5M at seed in 2019. Total funding to date: $257M across seven rounds including grants from NIH. Big Pharma syndicate includes Regeneron Pharmaceuticals, Amgen Ventures, and Eli Lilly; ICONIQ joined as a new investor in the Series B alongside existing leads FPV Ventures and Playground Global.
Company Profile
CEO
Jacob Becraft
Founded
2017
HQ
Boston, MA
Employees
~100
Total Raised
$257.2M
Growth
Pre-revenue clinical-stage biotech
Last Round
Series B — $153M (Aug 2025) · Lead: Kinnevik
IPO Status
private
Fundraising Status
Series B · $153M · 1y ago
privateTotal raised $257.2M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series B
$153M
Aug 2025
Kinnevik
—
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
2
2 active · 2 recruiting
Lead phase
Phase 2
most advanced registered study
Focus areas
Advanced Solid Tumor
Latest trial start
2026-06-30
Name-verified against lead sponsor "Strand Therapeutics Inc." on ClinicalTrials.gov as of 2026-08-19. Verify on ClinicalTrials.gov ↗
Talent Signal
Hiring trend
▶ Hiring steady
25% of roles posted in last 30d
Open roles
4
via greenhouse
Product-build share
50%
engineering, research, product, design
Trajectory
steady
product-led hiring — 50% of open roles build product; the rest are go-to-market and G&A.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Scientist / Senior Scientist, Process Sciences and InnovationSenior / Principal Associate Scientist, Advanced Cell EngineeringAssociate, Corporate DevelopmentSenior Vice President of Regulatory Sciences
Counted from Strand Therapeutics's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Jacob BecraftTasuku KitadaRon Weiss
Investors
Kinnevik · ICONIQ Capital · FPV Ventures · Playground Global · ANRI · Redmile Group · Regeneron Ventures · Amgen Ventures · Eli Lilly · ARCH Venture Partners · Andreessen Horowitz (a16z Bio)
Products
STX-001 (intratumoral mRNA for solid tumors, in clinic)
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q3. Refreshed quarterly.